| Hazard Information | Back Directory | [Uses]
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement[1][2]. | [in vivo]
Orticumab (10 mg/mouse; i.p.; once weekly for 3 weeks) reduces atherosclerosis in the aortic arch, decreases the CD68-macrophage subvalvular plaque staining[1].
| Animal Model: | B6.lpr.ApoE-/- mice (18-week-old) fed with high-fat diet (HFD)[1] | | Dosage: | 10 mg/mouse | | Administration: | Intraperitoneal injection; once weekly for 3 weeks | | Result: | Reduced atherosclerosis in the aortic arch by 42.8%, decreased the CD68-macrophage subvalvular plaque staining by 30.5%. |
| [References]
[1] Yao Mattisson I, et al. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascul Pharmacol. 2021 Oct;140:106863. DOI:10.1016/j.vph.2021.106863
[2] Liang BC, et al. Compositions and methods with anti-ApoB100 antibody or fragment for treatment of psoriasis: World Intellectual Property Organization, WO2019232070 A1. 2019-12-05. |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
|